Nah, Avexa's product is way too advanced in trial... Biota adds value in the very early stages of development, they would take significant risk trying to run late stage trials themselves or market drugs directly. I would prefer buying a new platform, perhaps even Novogen. DNDN has seen success in trials, that would be another area to look at.
- Forums
- ASX - By Stock
- BTA
- new cdc guidelines should boost revenue
new cdc guidelines should boost revenue, page-7
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)